🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

U.S. government awards $45 million for long COVID clinics

Published 09/20/2023, 10:59 AM
Updated 09/21/2023, 10:26 AM
© Reuters. Medical staff treat a coronavirus disease (COVID-19) patient in the Intensive Care Unit (ICU) at the Cleveland Clinic in Cleveland, Ohio, U.S., January 7, 2022.  REUTERS/Shannon Stapleton/File Photo

By Ahmed Aboulenein

WASHINGTON (Reuters) - The U.S. government is awarding $45 million in grants to help clinics treating long COVID develop new models of care and expand access, the Department of Health and Human Services (HHS) said on Wednesday.

Nine clinics will receive $1 million grants annually over the next five years through the Agency for Healthcare Research and Quality (AHRQ) within HHS, the department said.

President Joe Biden had tasked HHS last year with developing a national action plan to tackle long COVID, a complex, multi-symptom condition that arises months after a COVID-19 infection and leaves many of its sufferers unable to work.

"The Biden-Harris Administration is supporting patients, doctors and caregivers by providing science-based best practices for treating long COVID, maintaining access to insurance coverage, and protecting the rights of workers as they return to jobs while coping with the uncertainties of their illness," said HHS Secretary Xavier Becerra.

The funding will be used for increasing in-person and virtual visits, establishing new satellite clinics, and an education initiative aimed at growing referrals. Limited knowledge and acceptance among clinicians has contributed to delays in diagnoses and referrals.

It will also go towards social services, hiring interpreters, group patient programs, and behavioral health support. The grants prioritize access for underserved, rural, vulnerable, and minority populations that are disproportionately impacted by long COVID.

The condition affects nearly 7% of all U.S. adults and 2.3% of the overall population and has cost an estimated $386 billion in lost wages, savings and medical bills, according to an analysis in April by the Solve Long Covid Initiative, a non-profit research and advocacy group.

© Reuters. Medical staff treat a coronavirus disease (COVID-19) patient in the Intensive Care Unit (ICU) at the Cleveland Clinic in Cleveland, Ohio, U.S., January 7, 2022.  REUTERS/Shannon Stapleton/File Photo

More than 200 symptoms have been linked to the syndrome - including extreme fatigue, difficulty thinking, headaches, dizziness when standing, sleep problems, chest pain, blood clots, immune dysregulation, and even diabetes.

No proven treatments are available but research is underway. The National Institute of Health (NIH) is conducting a $1.15 billion effort, the RECOVER program, which launched two clinical trials in July that will evaluate at least four potential treatments.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.